Cvrx, Inc.
A maker of implantable medical devices, CVRx builds Barostim, a tiny device that sits under the skin and gently pulses the body's own carotid baroreceptors to ease the symptoms of heart failure — the first device of its kind approved by the FDA. Founded in 2001 by two engineers, it took its name from a mashup of "cardiovascular" and "Rx," the shorthand for prescription or therapy.
Granted 3.9K · Sold 82.3K
Granted 8.7K · Bought 448.3K
Granted 8.7K · Bought 50.8K
Granted 257.0K · Bought 35.0K · Sold 7.8K
Granted 98.4K · Sold 1.7K
Granted 90.0K · Sold 4.0K
Granted 61.0K · Sold 1.3K
Granted 81.3K · Sold 11.6K
Granted 25.3K · Bought 8.5K
Granted 34.0K
Granted 49.0K
Granted 31.6K
Granted 29.0K
Granted 43.8K
Granted 14.0K
Granted 8.7K
Granted 8.7K
Granted 8.7K
Granted 778
Granted 1.2K
Granted 316
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Johnson & Johnson +1 co-filer10% owner · 24 transactions | +15.1% | 4.02M | 3.9K | — | 82.3K |
| Nielsen Kirk G.Director · 18 transactions | — | 1.92M | 8.7K | 448.3K | — |
| Jain Mudit K.Director · 8 transactions | +6.4% | 994.6K | 8.7K | 50.8K | — |
| Hykes KevinPRES & CEO, Director · 5 transactions | — | 284.2K | 257.0K | 35.0K | 7.8K |
| Oasheim JaredCHIEF FINANCIAL OFFICER · 9 transactions | — | 96.7K | 98.4K | — | 1.7K |
| John Robert AllenChief Revenue Officer · 3 transactions | — | 86.0K | 90.0K | — | 4.0K |
| Adamson Philip B.Chief Medical Officer · 3 transactions | — | 61.6K | 61.0K | — | 1.3K |
| Verrastro PaulCHIEF MKTG & STRAT OFFICER · 17 transactions | — | 60.6K | 81.3K | — | 11.6K |
| Slattery Joseph PDirector · 21 transactions | +608.6% | 39.4K | 25.3K | 8.5K | — |
| Morrison GregoryCHIEF HUMAN RESOURCES OFFICER · 1 transaction | — | 34.0K | 34.0K | — | — |
| Bruhn-Ding DeanVP of Reg. Affairs and QA · 14 transactions | +480.9% | 32.8Kas of Feb 2022 | 49.0K | — | — |
| Binkowski BrentCHIEF OPERATING OFFICER · 2 transactions | — | 31.6K | 31.6K | — | — |
| Dale Michael DDirector · 1 transaction | — | 29.0K | 29.0K | — | — |
| Yared NadimCHIEF EXECUTIVE OFFICER, Director · 12 transactions | — | 24.3Kas of Jan 2024 | 43.8K | — | — |
| Brintnall JohnCHIEF STRATEGY OFFICER AND SEC · 6 transactions | +38.4% | 24.3Kas of Apr 2022 | 14.0K | — | — |
| Ballinger Kevin J.Director · 1 transaction | — | 8.7K | 8.7K | — | — |
| Hill, Mitch C.Director · 1 transaction | — | 8.7K | 8.7K | — | — |
| Shadan MarthaDirector · 1 transaction | — | 8.7K | 8.7K | — | — |
| Galle LizVP OF GLOBAL CLINICAL RESEARCH · 1 transaction | — | 778as of Oct 2023 | 778 | — | — |
| Palmer Craig E.SVP, U.S. SALES · 4 transactions | — | 674as of Mar 2024 | 1.2K | — | — |
| Behbahani AliDirector · 1 transaction | — | 316as of Dec 2023 | 316 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +434.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.